Premium
ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
Author(s) -
Tam C.S.,
Quach H.,
Nicol A.,
Badoux X.,
Rose H.,
Prince H.M.,
Leahy M.F.,
Eek R.,
Wickham N.,
Patil S.S.,
Huang J.,
Prathikanti R.,
Wang L.,
Reed W.,
Flinn I.W.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.81_2629
Subject(s) - medicine , ibrutinib , bruton's tyrosine kinase , obinutuzumab , neutropenia , chronic lymphocytic leukemia , gastroenterology , tyrosine kinase , oncology , leukemia , chemotherapy , receptor